Your browser is no longer supported. Please, upgrade your browser.
Olema Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own14.40% Shs Outstand38.13M Perf Week1.26%
Market Cap1.63B Forward P/E- EPS next Y-1.26 Insider Trans40.58% Shs Float32.92M Perf Month-3.11%
Income-14.90M PEG- EPS next Q-0.18 Inst Own17.20% Short Float2.16% Perf Quarter-
Sales- P/S- EPS this Y-96.40% Inst Trans- Short Ratio3.74 Perf Half Y-
Book/sh- P/B- EPS next Y-22.30% ROA- Target Price60.67 Perf Year-
Cash/sh3.35 P/C12.72 EPS next 5Y- ROE- 52W Range35.73 - 60.27 Perf YTD-11.34%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.27% Beta-
Dividend %- Quick Ratio24.50 Sales past 5Y- Gross Margin- 52W Low19.31% ATR2.76
Employees21 Current Ratio24.50 Sales Q/Q- Oper. Margin- RSI (14)46.14 Volatility5.11% 6.42%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.36 Prev Close41.86
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume190.16K Price42.63
Recom1.50 SMA20-4.46% SMA50-6.50% SMA200-6.50% Volume68,573 Change1.84%
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
Dec-31-20 03:42PM  
Dec-17-20 07:00AM  
Dec-07-20 07:39AM  
Dec-03-20 05:18PM  
Nov-23-20 04:01PM  
Nov-20-20 01:33PM  
Nov-19-20 06:39PM  
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cormorant Asset Management, LPFormer 10% OwnerNov 23Buy19.00425,0008,075,0003,270,544Nov 23 04:59 PM
Graham G. WalmsleyDirectorNov 23Buy19.001,160,00022,040,0001,160,000Nov 23 04:35 PM